The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2024 | Early detection and interception across hematological cancers
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, briefly summarizes a session on early detection and interception across a range of hematological malignancies. Precursors discussed include clonal hematopoiesis of indeterminate potential (CHIP), monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and monoclonal B-cell lymphocytosis (MBL). Dr Ghobrial highlights that investigating common precursors allows for a greater understanding of disease progression and the best strategies for interception to prevent the development of leukemia, lymphoma, and myeloma. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
